Our Portfolio

Aera Therapeutics

Approach: Aera Therapeutics is developing lipid nanoparticle-based in vivo CAR-T therapies designed to modulate the immune system through B cell depletion

Strategic Area: Immune Modulation

AltruBio

Approach: AltruBio is a clinical stage company with a tetravelent antibody targeting PSGL1 for T cell mediated autoimmune and autoinflammatory diseases.

Strategic Area: Immunotherapies

Aspect Biosystems

Approach: AspectBio is leveraging proprietary 3D printing technology to design an immune shielded beta cell transplantation product.

Strategic Area: B-Cell Replacement

Aurimi Therapeutics

Approach: Precision medicine platform developing small molecules blockers of autoimmunity

Strategic Area: Immunotherapies

Bigfoot Biomedical

Approach: Developing a comprehensive diabetes management ecosystem to reduce the burden of diabetes for insulin-dependent individuals living with T1D and T2D

Strategic Area: Improving Lives

Biolinq

Approach: Developing a wirelessly-enabled biosensor patch capable of continuously monitoring multiple biomarkers. Initially focused on a minimally-invasive continuous glucose monitor (CGM) for people with diabetes

Strategic Area: Improving Lives

Capillary Biomedical

Approach: Clinical-stage novel extended wear insulin infusion set technology to improve the lives of people with T1D on insulin pump therapy

Strategic Area: Improving Lives

Century Therapeutics

Approach: Cell Therapy company developing allogeneic iPSC-derived cell therapies with a next-gen immune evasion approach, including an islet replacement product for T1D (preclinical) and immune cell therapies for autoimmune disease (clinical).

Strategic Area: Beta Cell Therapies

COUR Pharmaceuticals

Approach: COUR’s nanoparticle therapies deliver disease-specific antigen or allergen to antigen-presenting cells (APCs) in the spleen and liver via natural, non-inflammatory, phagocytic pathways.

Strategic Area: Immunotherapies

Diasome Pharmaceuticals

Approach: Developing a clinical stage liver-targeted insulin for improved glycemic control

Strategic Area: Improving Lives

DiogenX

Approach: Developing a regenerative agent to restore functional beta cell mass

Strategic Area: Beta Cell Therapies

Egle Therapeutics

Approach: Engineered and targeted cytokines to treat autoimmune diseases

Strategic Area: Immunotherapies

Eledon Pharmaceuticals

Approach: Clinical stage transplantation company

Strategic Area: Immunotherapies

GentiBio

Approach: Advancing a novel treatment modality for T1D enabling next-generation immune therapies

Strategic Area: Immunotherapies

Immunocore

Approach: Soluble TCR bi-specific approach for safer, durable, tissue-specific immunomodulation to preserve beta cells

Strategic Area: Immunotherapies

Inversago Pharma

Approach: Developing an oral drug to promote beta cell functional recovery

Strategic Area: Beta Cell Therapies

Jaguar Gene Therapy

Approach: Leveraging gene therapy for patients suffering from severe genetic diseases.

Strategic Area: Beta Cell Therapies

Kriya Therapeutics

Approach: Using gene therapy to achieve insulin independence in established T1D

Strategic Area: Beta Cell Therapies

Mozart Therapeutics

Approach: Mozart Therapeutics is a Seattle-based clinical-stage company developing Treg bispecific engagers for autoimmune indications.

Strategic Area: Immunotherapies

Orizuru Therapeutics

Approach: Orizuru Therapeutics was founded out of research from Kyoto University and is developing iPSC derived islets and cardiomyocytes

Strategic Area: Beta Cell Therapies

Pandion Therapeutics

Approach: Islet-targeted immunotherapies for safer, durable treatments

Strategic Area: Immunotherapies

Protomer Technologies

Approach: Developing a highly-sensitive glucose-responsive insulin

Strategic Area: Improving Lives

Provention Bio

Approach: Building and advancing a diversified portfolio of advanced clinical-stage and pre commercial-stage candidates that intercept, prevent or delay the progression of debilitating, life-impacting, and life-threatening diseases such as type 1 diabetes, celiac disease, and lupus (NASDAQ: PRVB)

Strategic Area: Immunotherapies

Sab Biotherapeutics

Approach: Platform to development fully-human antibody therapies with improved safety and pharmacological properties for treating autoimmune and infectious diseases.

Strategic Area: Immunotherapies

Sana Biotechnology

Approach: Developing a cell replacement therapy using hypoimmune iPSC-derived islets to achieve insulin independence

Strategic Area: Beta Cell Therapies

Semma Therapeutics

Approach: Combining proprietary cells with state-of-the-art devices towards insulin independence

Strategic Area: Beta Cell Therapies

Sonoma Biotherapeutics

Approach: Developing a promising immune modulator to preserve beta cell function

Strategic Area: Immunotherapies

vTv Therapeutics

Approach: Activating liver glucokinase to decrease frequency of hypoglycemic events and lower HbA1c

Strategic Area: Improving Lives

ZagBio

Approach: Zag Bio is working to discover and develop therapies targeted directly to the thymus, with the goal of generating central immune tolerance.

Strategic Area: Immunotherapies

Zucara Therapeutics

Approach: Zucara Therapeutics is modulating alpha cell function to improve glycemic control and prevent hypoglycemic events

Strategic Area: Metabolic Control